Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.
6 February 2026. doid: 10.1111/jdv.70311
Koster NG, van den Reek JMPA, de Jong EMGJ, van Beugen S, van Laarhoven AIM, Haeck I, de Bruin-Weller M, Schuttelaar ML, Horvath B, Gostyński A, Knulst A, Vermeer MH, Nguyen L, Gerbens L, Spuls P, Middelkamp-Hup MA, Exadaktylos V, Niemeyer-van der Kolk T, Schrader AR, Sluijmers AM, Versteeg J, Arents BWM, van Ee I, van der Zon JLAG, de Leeuw M, de Leeuw T, van den Broek P, Berkhof C, Vellinga D, Weidinger S, Dubrac S, Li Y, van Steensel M, Marchetti-Deschmann M, Maurer M, van der Zee H, Damman J, Hijnen DJ, Wijk F, Seyger MMB, Röckmann H, Balak DMW, van Doorn MBA, Rissmann R,
View publicationThe Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)' will be conducted as a multicentre, parallel-cohort, open-label, observational, longitudinal basket study.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
